2023
Consensus report from the 10th Global Forum for Liver Magnetic Resonance Imaging: developments in HCC management
Taouli B, Ba-Ssalamah A, Chapiro J, Chhatwal J, Fowler K, Kang T, Knobloch G, Koh D, Kudo M, Lee J, Murakami T, Pinato D, Ringe K, Song B, Tabrizian P, Wang J, Yoon J, Zeng M, Zhou J, Vilgrain V. Consensus report from the 10th Global Forum for Liver Magnetic Resonance Imaging: developments in HCC management. European Radiology 2023, 33: 9152-9166. PMID: 37500964, PMCID: PMC10730664, DOI: 10.1007/s00330-023-09928-y.Peer-Reviewed Original ResearchConceptsGadoxetic acid-enhanced magnetic resonance imagingLiver magnetic resonance imagingMagnetic resonance imagingHCC managementResonance imagingOutcome of HCCScreening/surveillanceLiver cancer screeningPrediction of prognosisWestern guidelinesCancer screeningLiver surgeonsLiver surgeryConsensus statementHCC screeningTreatment responseConsensus reportLiver cancerInterventional radiologistsClinical relevanceClinical practiceGadoxetic acidEmerging DataHCCDiagnosis
2022
Experimental VX2 Rabbit Liver Tumor Model in Carbon Tetrachloride–Induced Cirrhosis of the Liver
Santana J, Shewarega A, Nam D, Kahl V, Madoff D, Zhang X, Chapiro J. Experimental VX2 Rabbit Liver Tumor Model in Carbon Tetrachloride–Induced Cirrhosis of the Liver. Journal Of Vascular And Interventional Radiology 2022, 34: 404-408.e1. PMID: 36473611, PMCID: PMC11037556, DOI: 10.1016/j.jvir.2022.11.026.Peer-Reviewed Original ResearchConceptsLiver cirrhosisMale New Zealand white rabbitsRabbit liver tumor modelCirrhotic liver backgroundReproducible tumor growthVX2 liver cancerLeft hepatic lobeNew Zealand white rabbitsDuration of treatmentLiver tumor modelCross-sectional imagingVX2 rabbit liver tumor modelZealand white rabbitsHepatic lobeHistopathological evaluationMajor underlying factorHepatic tumorsIntragastric administrationHepatocellular carcinomaLiver tumorsLiver cancerCirrhosisUnmet needTumor growthVX2 tumors
2021
Deep learning–assisted differentiation of pathologically proven atypical and typical hepatocellular carcinoma (HCC) versus non-HCC on contrast-enhanced MRI of the liver
Oestmann PM, Wang CJ, Savic LJ, Hamm CA, Stark S, Schobert I, Gebauer B, Schlachter T, Lin M, Weinreb JC, Batra R, Mulligan D, Zhang X, Duncan JS, Chapiro J. Deep learning–assisted differentiation of pathologically proven atypical and typical hepatocellular carcinoma (HCC) versus non-HCC on contrast-enhanced MRI of the liver. European Radiology 2021, 31: 4981-4990. PMID: 33409782, PMCID: PMC8222094, DOI: 10.1007/s00330-020-07559-1.Peer-Reviewed Original ResearchConceptsNon-HCC lesionsHepatocellular carcinomaHCC lesionsAtypical imagingGrading systemLI-RADS criteriaAtypical imaging featuresPrimary liver cancerTypical hepatocellular carcinomaAtypical hepatocellular carcinomaContrast-enhanced MRISensitivity/specificityLiver transplantMethodsThis IRBRetrospective studyLiver malignanciesImaging featuresLiver cancerAtypical featuresConclusionThis studyLesionsMRIClinical applicationCarcinomaImage-based diagnosis
2020
Automated feature quantification of Lipiodol as imaging biomarker to predict therapeutic efficacy of conventional transarterial chemoembolization of liver cancer
Stark S, Wang C, Savic LJ, Letzen B, Schobert I, Miszczuk M, Murali N, Oestmann P, Gebauer B, Lin M, Duncan J, Schlachter T, Chapiro J. Automated feature quantification of Lipiodol as imaging biomarker to predict therapeutic efficacy of conventional transarterial chemoembolization of liver cancer. Scientific Reports 2020, 10: 18026. PMID: 33093524, PMCID: PMC7582153, DOI: 10.1038/s41598-020-75120-7.Peer-Reviewed Original ResearchConceptsConventional transarterial chemoembolizationLipiodol depositionTransarterial chemoembolizationLiver cancerPeripheral depositionLipiodol depositsTherapeutic efficacyNecrotic tumor areasBaseline MRITherapy optionsTumor responseTreatment responseTumor volumeLiver lesionsLipiodolH postTumor areaH-CTHounsfield unitsBiomarkersChemoembolizationHigh rateTumorsCancerImproved responseFibronodular hepatocellular carcinoma—a new variant of liver cancer: clinical, pathological and radiological correlation
Tefera J, Revzin M, Chapiro J, Savic L, Mulligan D, Batra R, Taddei T, Jain D, Zhang X. Fibronodular hepatocellular carcinoma—a new variant of liver cancer: clinical, pathological and radiological correlation. Journal Of Clinical Pathology 2020, 74: 31-35. PMID: 32430483, PMCID: PMC7674234, DOI: 10.1136/jclinpath-2020-206574.Peer-Reviewed Original ResearchConceptsAdvanced Barcelona Clinic Liver Cancer stageBarcelona Clinic Liver Cancer stageScirrhous HCCMultiple rounded nodulesNon-peripheral washoutLiver Cancer stageRadiological featuresClinical featuresRadiological correlationCarcinoma variantsCancer stageHCC casesHepatocellular carcinomaLiver cancerFibrotic liverConventional HCCHCCLower ratesHigh rateRounded nodulesProgressionDistinct patternsCarcinomaSpecific variantsLesionsLipiodol as an Imaging Biomarker of Tumor Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and Secondary Liver Cancer
Miszczuk MA, Chapiro J, Geschwind JH, Thakur V, Nezami N, Laage-Gaupp F, Kulon M, van Breugel JMM, Fereydooni A, Lin M, Savic LJ, Tegel B, Wahlin T, Funai E, Schlachter T. Lipiodol as an Imaging Biomarker of Tumor Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and Secondary Liver Cancer. Translational Oncology 2020, 13: 100742. PMID: 32092672, PMCID: PMC7036424, DOI: 10.1016/j.tranon.2020.01.003.Peer-Reviewed Original ResearchMolecular Imaging of Extracellular Tumor pH to Reveal Effects of Locoregional Therapy on Liver Cancer Microenvironment
Savic LJ, Schobert I, Peters D, Walsh JJ, Laage-Gaupp F, Hamm CA, Tritz N, Doemel LA, Lin M, Sinusas A, Schlachter T, Duncan JS, Hyder F, Coman D, Chapiro J. Molecular Imaging of Extracellular Tumor pH to Reveal Effects of Locoregional Therapy on Liver Cancer Microenvironment. Clinical Cancer Research 2020, 26: 428-438. PMID: 31582517, PMCID: PMC7244230, DOI: 10.1158/1078-0432.ccr-19-1702.Peer-Reviewed Original ResearchConceptsMR spectroscopic imagingLocoregional therapyLiver cancer microenvironmentConventional transarterial chemoembolizationNew Zealand white rabbitsTumor pHMost liver tumorsZealand white rabbitsMolecular imaging paradigmsPositive therapeutic outcomesTumor residualsTransarterial chemoembolizationTumor devascularizationHistopathologic markersViable tumorSurrogate biomarkerLiver tumorsLiver cancerTumor enhancementLiver parenchymaMetabolic markersMultiparametric MRITherapeutic outcomesHIF-1αVX2 tumors
2019
Fluorodeoxyglucose PET for Monitoring Response to Embolotherapy (Transarterial Chemoembolization) in Primary and Metastatic Liver Tumors
Schobert I, Chapiro J, Pucar D, Saperstein L, Savic LJ. Fluorodeoxyglucose PET for Monitoring Response to Embolotherapy (Transarterial Chemoembolization) in Primary and Metastatic Liver Tumors. PET Clinics 2019, 14: 437-445. PMID: 31472741, DOI: 10.1016/j.cpet.2019.06.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, HepatocellularChemoembolization, TherapeuticFemaleFluorodeoxyglucose F18HumansInfusions, Intra-ArterialLiver NeoplasmsMagnetic Resonance ImagingMaleMiddle AgedMonitoring, PhysiologicMultimodal ImagingNeoplasm MetastasisPositron-Emission TomographyRadiopharmaceuticalsSensitivity and SpecificitySurvival AnalysisTomography, X-Ray ComputedTreatment OutcomeTumor MicroenvironmentConceptsTransarterial chemoembolizationLiver tumorsFluorine-18 fluorodeoxyglucose PETEfficacy of embolotherapyCross-sectional imaging techniquesMetastatic liver tumorsCancer cell glycolysisLocal recurrenceFluorodeoxyglucose PETTumor necrosisLiver cancerMorphologic changesCell glycolysisEmbolotherapyTumorsMonitoring responseIndividual molecular characteristicsMolecular characteristicsImaging techniquesChemoembolizationResponsePatientsRecurrencePETTherapyTheranostic application of lipiodol for transarterial chemoembolization in a VX2 rabbit liver tumor model
van Breugel JMM, Geschwind JF, Mirpour S, Savic LJ, Zhang X, Duran R, Lin M, Miszczuk M, Liapi E, Chapiro J. Theranostic application of lipiodol for transarterial chemoembolization in a VX2 rabbit liver tumor model. Theranostics 2019, 9: 3674-3686. PMID: 31281506, PMCID: PMC6587357, DOI: 10.7150/thno.32943.Peer-Reviewed Original ResearchConceptsOil Red OPerfusion indexMicrovascular densityLipiodol depositionLiver cancerTherapeutic efficacyVX2 tumorsContrast-enhanced CT scanRabbit liver tumor modelTumor-specific functionsNon-tumoral liverLiver tumor modelRadiological-pathological correlationVX2 rabbit liver tumor modelPortal flowTransarterial chemoembolizationLeft lobeLipiodol retentionTherapeutic managementPatient responseTumor vascularityTumor volumeArterial flowCT scanTumor perfusion
2017
Science to Practice: Molecular-targeted Drug Delivery in Combination with Radiofrequency Ablation of Liver Cancer: A Magic Bullet?
Adam LC, Murali N, Chapiro J, Geschwind JF. Science to Practice: Molecular-targeted Drug Delivery in Combination with Radiofrequency Ablation of Liver Cancer: A Magic Bullet? Radiology 2017, 285: 333-335. PMID: 29045226, PMCID: PMC5673055, DOI: 10.1148/radiol.2017171527.Peer-Reviewed Original ResearchConceptsRadiofrequency ablationRF ablationHepatocellular carcinoma mouse modelTechnical success rateSurvival end pointsChemotherapeutic drug concentrationsCarcinoma mouse modelAnimal tumor modelsTumor-penetrating peptideClinical outcomesTarget lesionsDrug delivery systemsLiver cancerMouse modelTumor modelEnd pointDrug concentrationsDrug deliverySuccess rateTumor treatmentToxic effectsDelivery systemAblationMagic bulletLesions
2016
Intra-arterial therapies for liver cancer: assessing tumor response
Stroehl YW, Letzen BS, van Breugel JM, Geschwind JF, Chapiro J. Intra-arterial therapies for liver cancer: assessing tumor response. Expert Review Of Anticancer Therapy 2016, 17: 119-127. PMID: 27983883, DOI: 10.1080/14737140.2017.1273775.Peer-Reviewed Original Research
2015
Targeting glucose metabolism in cancer: a new class of agents for loco-regional and systemic therapy of liver cancer and beyond?
Savic LJ, Chapiro J, Duwe G, Geschwind J. Targeting glucose metabolism in cancer: a new class of agents for loco-regional and systemic therapy of liver cancer and beyond? Hepatic Oncology 2015, 3: 19-28. PMID: 26989470, PMCID: PMC4792180, DOI: 10.2217/hep.15.36.Peer-Reviewed Original ResearchIntra-arterial therapyHepatocellular carcinomaCancer-related deathUnresectable diseaseCancer cell metabolismSystemic therapyTherapeutic optionsTumor controlPrevalent cancerLiver cancerGlucose metabolismAntiglycolytic agentsTumor growthSystemic toxicitySelective anticancer therapyTherapyAnticancer therapyCancerNew targetsWarburg effectMolecular featuresAntiglycolytic drugsCell metabolismDelivery methodsMetabolismFeasibility of a Modified Cone-Beam CT Rotation Trajectory to Improve Liver Periphery Visualization during Transarterial Chemoembolization.
Schernthaner RE, Chapiro J, Sahu S, Withagen P, Duran R, Sohn JH, Radaelli A, van der Bom IM, Geschwind JF, Lin M. Feasibility of a Modified Cone-Beam CT Rotation Trajectory to Improve Liver Periphery Visualization during Transarterial Chemoembolization. Radiology 2015, 277: 833-41. PMID: 26000642, PMCID: PMC4654716, DOI: 10.1148/radiol.2015142821.Peer-Reviewed Original ResearchConceptsCone-beam CTTransarterial chemoembolizationLiver volumeRadiation exposureInstitutional review board-approved studyPeripheral hepatic tumorsSecondary liver cancerCT radiation exposureCone beam CT examinationsBoard-approved studyTumor detectabilityRadiation exposure reductionHepatic tumorsCT examinationsLiver cancerCT protocolPatientsCone beamMagnetic resonance imagesCT indicesC-arm rotatesCTTumorsExposure reductionRank testA new angiographic imaging platform reduces radiation exposure for patients with liver cancer treated with transarterial chemoembolization
Schernthaner RE, Duran R, Chapiro J, Wang Z, Geschwind JF, Lin M. A new angiographic imaging platform reduces radiation exposure for patients with liver cancer treated with transarterial chemoembolization. European Radiology 2015, 25: 3255-3262. PMID: 25956933, PMCID: PMC4595540, DOI: 10.1007/s00330-015-3717-0.Peer-Reviewed Original ResearchConceptsDose area productDigital subtraction angiographyTransarterial chemoembolizationCone-beam CTRadiation exposureLiver cancerDSA image qualityCumulative dose area productSecondary liver cancerLiver cancer patientsTwo-arm trialSignificant differencesResultsBoth cohortsDiagnostic image qualityPatient characteristicsConsecutive patientsTumor burdenTACE proceduresCancer patientsSubtraction angiographyPatientsHIPAA compliantDigital fluoroscopyProcedure courseIndependent readers
2013
Percutaneous therapies of hepatocellular carcinoma—an update
Chapiro J, Geschwind JF. Percutaneous therapies of hepatocellular carcinoma—an update. Chinese Clinical Oncology 2013, 2: 36-36. PMID: 25841915, DOI: 10.3978/j.issn.2304-3865.2013.07.04.Peer-Reviewed Original ResearchIntra-arterial therapyHepatocellular carcinomaSpecific therapeutic algorithmsAvailable clinical evidenceEarly-stage diseaseIntra-arterial approachEnd-stage diseaseLocal tumor controlPrimary liver cancerTreatment of patientsTherapeutic algorithmEthanol ablationTransarterial chemoembolizationClinical evidencePatient groupTumor controlPercutaneous techniquesRadiofrequency ablationSuch therapyTherapeutic spectrumAblative techniquesPercutaneous therapyLiver cancerSystemic toxicityTherapyIntraarterial therapies for primary liver cancer: state of the art
Chapiro J, Tacher V, Geschwind JF. Intraarterial therapies for primary liver cancer: state of the art. Expert Review Of Anticancer Therapy 2013, 13: 1157-1167. PMID: 24099626, DOI: 10.1586/14737140.2013.845528.Peer-Reviewed Original ResearchConceptsPrimary liver cancerTreatment of patientsIntraarterial therapyHepatocellular carcinomaLiver cancerIntermediate-stage diseaseOfficial treatment guidelinesAvailable clinical evidenceEffective local tumor controlLocal tumor controlReduced systemic toxicityIntraarterial approachStage diseaseTransarterial chemoembolizationTreatment guidelinesClinical evidenceHepatic malignanciesTumor controlSystemic toxicityTherapyScientific rationalePatientsCancerTreatmentChemoembolization